Whalesbook
ICICI Direct Elevates Akums Drugs Outlook, Retains BUY Rating
ICICI Direct has reaffirmed its positive stance on Akums Drugs and Pharmaceuticals Limited, issuing a strong BUY recommendation and increasing the target price to INR 600. This upgrade follows a detailed analysis of the company's performance and future prospects, particularly within its Contract Development and Manufacturing Organization (CDMO) segment.
The Core Issue
For several past quarters, Akums Drugs and Pharmaceuticals has faced pressure on its growth due to a slump in the prices of key Active Pharmaceutical Ingredients (APIs). These price declines have directly impacted the performance of its CDMO business. However, the latest report suggests a turning point, with API prices now showing signs of stabilization. This stabilization is expected to alleviate the downward pressure and pave the way for renewed growth in the CDMO vertical.
Financial Implications
ICICI Direct forecasts that the CDMO segment will experience single-digit growth in the second half of the fiscal year 2026 (H2FY26). Crucially, the company has secured significant new export contracts. These include a USD 25 million revenue stream from Zambia starting in FY27E and a Euro 35 million revenue stream from Europe commencing in FY28E. These international agreements are pivotal, expected to drive overall revenue growth to approximately 14% from FY26 through FY28. Furthermore, these contracts are anticipated to provide a substantial boost to the company's profit margins.
In light of these positive developments, ICICI Direct has revised its earnings per share (EPS) estimates upwards. The FY27E EPS has been increased by approximately 4%, and the FY28E EPS by around 20%, reflecting the improved margin expectations stemming from the new export deals.
Outlook
The brokerage firm highlights that Akums Drugs and Pharmaceuticals is trading at an attractive Price-to-Book Value (P/BV) multiple. Currently, it stands at 1.9 times its estimated FY27 book value and 1.6 times its estimated FY28 book value. This valuation is considered compelling, especially given the company's dominant position within the Indian pharmaceutical manufacturing landscape. Based on this, ICICI Direct has retained its BUY rating and adjusted the target price upwards from INR 565 to INR 600.
Impact
This positive research report from ICICI Direct is likely to influence investor sentiment towards Akums Drugs and Pharmaceuticals. The confirmation of a BUY rating, coupled with an increased price target and robust growth projections driven by export contracts, could lead to increased demand for the stock. Investors may view the current valuation as an opportune entry point, potentially driving the stock price higher in the short to medium term. The news reinforces confidence in the company's strategic direction and its ability to navigate market challenges.
Impact Rating: 7/10
Difficult Terms Explained
- API (Active Pharmaceutical Ingredient): The biologically active component in a pharmaceutical drug that produces the intended health effects.
- CDMO (Contract Development and Manufacturing Organization): A company that offers services for the development and manufacturing of drugs on a contract basis for other pharmaceutical companies.
- FY27E / FY28E: Estimated figures for the fiscal year 2027 and fiscal year 2028, respectively. The 'E' denotes 'Estimate'.
- EPS (Earnings Per Share): A company's net profit divided by the number of its outstanding common shares, indicating profitability per share.
- P/BV (Price-to-Book Value): A valuation ratio that compares a company's market price per share to its book value per share. It is used to evaluate how much investors are willing to pay for each dollar of a company's net assets.